Mechanism of action and selectivity of acyclovir

1982/07/01 by Gertrude B. Elion · 26 citations
Biochemistry, Genetics and Molecular Biology · Chemistry · Immunology and Microbiology · Medicine · #Aciclovir #Biochemistry #Biology #Chemistry #DNA #DNA polymerase #Enzyme #GTP' #Guanosine triphosphate #Herpes simplex virus #Herpesviridae #Herpesvirus Infections and Treatments #Nucleoside #Polymerase #Primer (cosmetics) #Thymidine #Thymidine kinase #Toxin Mechanisms and Immunotoxins #Vero cell #Viral disease #Virology #Virus #Virus-based gene therapy research

paper · doi:10.1016/0002-9343(82)90055-9

openalex publication_date 1982/07/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29

Cited by

• Herpesvirus Polymerase Inhibitors
• Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. [europepmc]
• Progress in the development of new therapies for herpesvirus infections. [europepmc]
• Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. [europepmc]
• Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. [europepmc]
• Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors. [europepmc]
• Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. [europepmc]
• The effects of antiviral treatment on breast cancer cell line. [europepmc]
• Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer's Disease. [europepmc]
• Antiviral Therapies for Herpesviruses: Current Agents and New Directions. [europepmc]
• Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea. [europepmc]
• An Intra-Vaginal Zinc Oxide Tetrapod Nanoparticles (ZOTEN) and Genital Herpesvirus Cocktail Can Provide a Novel Platform for Live Virus Vaccine. [europepmc]
• CRISPR-Cas based targeting of host and viral genes as an antiviral strategy. [europepmc]
• Antiviral peptides as promising therapeutic drugs. [europepmc]
• Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections. [europepmc]
• Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. [europepmc]
• Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase. [europepmc]
• Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. [europepmc]
• Herpes Simplex Virus Type 1 Clinical Isolates Respond to UL29-Targeted siRNA Swarm Treatment Independent of Their Acyclovir Sensitivity. [europepmc]
• Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. [europepmc]
• Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2. [europepmc]
• Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma. [europepmc]
• NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. [europepmc]
• Impact of Cultured Neuron Models on α-Herpesvirus Latency Research. [europepmc]
• Targeting SARS-CoV-2 Non-Structural Proteins. [europepmc]
• The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis. [europepmc]